Free Trial

Solid Biosciences (SLDB) Stock Forecast & Price Target

$8.91
-0.73 (-7.57%)
(As of 07/17/2024 ET)

Solid Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 9 Wall Street analysts who have issued ratings for Solid Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for SLDB.

Consensus Price Target

$16.17
81.44% Upside
High Forecast$20.00
Average Forecast$16.17
Low Forecast$12.00

According to the 9 analysts' twelve-month price targets for Solid Biosciences, the average price target is $16.17. The highest price target for SLDB is $20.00, while the lowest price target for SLDB is $12.00. The average price target represents a forecasted upside of 81.44% from the current price of $8.91.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Buy
Moderate Buy
Buy
Hold
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$16.17$16.00$18.25$52.50
Forecasted Upside81.44% Upside73.20% Upside43.76% Upside460.54% Upside
Get Solid Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

SLDB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SLDB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Solid Biosciences Stock vs. The Competition

TypeSolid BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.71
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside81.85% Upside1,213.28% Upside7.69% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/15/2024JPMorgan Chase & Co.
3 of 5 stars
 UpgradeNeutral ➝ Overweight$10.00 ➝ $15.00+89.63%
6/24/2024Leerink Partnrs
0 of 5 stars
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/24/2024SVB Leerink
1 of 5 stars
 UpgradeMarket Perform ➝ Outperform$12.00 ➝ $12.00+85.76%
6/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00+203.03%
5/20/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. He
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00+78.77%
5/16/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$21.00 ➝ $18.00+95.02%
3/28/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/15/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+30.29%
9/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
8/12/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$105.00 ➝ $90.00+670.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:34 PM ET.

SLDB Forecast - Frequently Asked Questions

What is Solid Biosciences' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Solid Biosciences is $16.17, with a high forecast of $20.00 and a low forecast of $12.00.

Should I buy or sell Solid Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLDB shares.

Does Solid Biosciences's stock price have much upside?

According to analysts, Solid Biosciences's stock has a predicted upside of 88.61% based on their 12-month stock forecasts.

Has Solid Biosciences been upgraded by Wall Street analysts recently?

Over the previous 90 days, Solid Biosciences's stock had 3 upgrades by analysts.

What analysts cover Solid Biosciences?

Solid Biosciences has been rated by research analysts at Barclays, HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, and SVB Leerink in the past 90 days.

Do Wall Street analysts like Solid Biosciences more than its competitors?

Analysts like Solid Biosciences more than other "medical" companies. The consensus rating for Solid Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SLDB compares to other companies.


This page (NASDAQ:SLDB) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners